ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.

Your daily dose of the clinical news you may have missed.

A panelist discusses how contemporary therapeutic approaches enable successful management of atopic dermatitis through examination of real-world patient cases that demonstrate effective disease control strategies using the latest treatment options.

A panelist discusses how topical treatments for atopic dermatitis can be strategically selected and applied across the lifespan, with considerations for age-specific needs from infancy through adulthood.

A panelist discusses how effective coordination between primary care providers and dermatologists creates a complementary care model that optimizes atopic dermatitis management through shared decision-making, clear communication pathways, and defined roles for each specialty.

A panelist discusses how treatment selection for atopic dermatitis is influenced by multiple considerations including disease severity, patient age, affected body regions, comorbidities, previous treatment responses, and patient preferences.

A panelist discusses how topical JAK inhibitors and AhR agonists represent emerging therapeutic approaches for atopic dermatitis that target specific inflammatory pathways to provide effective symptom relief with distinct mechanisms of action.

A panelist discusses how topical PDE4 inhibitors provide an effective, non-steroidal treatment option for atopic dermatitis by reducing inflammation and improving symptoms with a favorable safety profile.

A panelist discusses how clinicians can select optimal topical treatments for atopic dermatitis by carefully weighing efficacy against potential side effects to create personalized management plans for patients.

A panelist discusses how primary care practitioners can implement efficient diagnostic protocols and treatment pathways to better manage atopic dermatitis patients within the constraints of busy clinical settings.

A panelist discusses how healthcare providers can effectively identify and manage atopic dermatitis flares across different age groups, highlighting the unique challenges and treatment approaches for both pediatric and adult populations.

Your daily dose of the clinical news you may have missed.

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Awareness of the psychological burden of eczema is improving, LeBovidge says, but if clinicians don't address mental health, patients and families will suffer in silence.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

Your daily dose of the clinical news you may have missed.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

Lepodisiran at 400 mg maintained reductions of Lp(a), an inherited risk factor for cardiovascular disease, at ~90% at 1 year and ~75% at 1.5 years, Eli Lilly reported.

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

Your daily dose of the clinical news you may have missed.

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.